CardiaTec is a pioneering TechBio company dedicated to transforming cardiovascular disease treatment through advanced computational modeling and multi-omics data analysis. By integrating genomics, epigenomics, transcriptomics, and proteomics from human cardiac tissues, CardiaTec aims to uncover novel therapeutic targets and develop first-in-class cardiovascular therapies. The company has established a proprietary multi-omics dataset, sourced from a network of 65 hospitals across the UK and US, to support its innovative research initiatives. Key Features and Functionality: - Comprehensive Multi-Omics Data Integration: CardiaTec combines various biological data layers to provide a holistic understanding of cardiovascular disease mechanisms. - Advanced Computational Modeling: Utilizing state-of-the-art AI algorithms, the company analyzes complex datasets to identify and prioritize dysregulated drug targets and disease-related pathways. - Proprietary Data Strategy: With access to human cardiac tissues and corresponding clinical annotations, CardiaTec has built the largest human cardiac tissue multi-omics database, enhancing the discovery of truly novel therapeutics. Primary Value and Problem Solved: Cardiovascular disease remains the leading cause of death globally, claiming approximately 20 million lives annually. Traditional therapeutic development has been hindered by a limited understanding of the disease's complex biology, resulting in stagnated innovation and investment. CardiaTec addresses this challenge by leveraging its proprietary multi-omics dataset and computational platform to decode the intricate mechanisms driving disease progression. This approach facilitates the discovery and development of novel, targeted therapies, aiming to improve patient outcomes and reduce the global burden of cardiovascular diseases.